The latest updates from AFAR.

Board Member in the News: Nir Barzilai on TAME trial in Business Insider

Jul 12

Board Member in the News: Nir Barzilai on TAME trial in Business Insider View MoreBACK

On July 7, 2017, Business Insider spotlighted AFAR Deputy Scientific Director Nir Barzilai, MD and the AFAR-managed TAME trial.

The feature story, A diabetes medication that costs 6 cents a pill could be a key to living longer, describes the history, affordability, and current usage of Metformin.

The story also highlights the Targeting Aging with Metformin (TAME) trial. It underscores its potential to change the way we approach aging by proving proof to the FDA that aging is a treatable condition. 

In his 2014 TED Talk, as quoted by Business Insider, Dr. Barzilai explains: "The FDA doesn't consider aging as something that can be prevented. And as long as that happens, your insurance company is not going to pay your bill if you take a drug and the pharmaceuticals are not going to develop the drugs because if nobody is going to pay for their use, why spend the money on that?"

The full article can be read here.

Nir Barzilai, MD is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and the Director of the Nathan Shock Centers of Excellence in the Biology of Aging at Albert Einstein College of Medicine.

For more information on the TAME Trial, we encourage you to view our TAME Trial FAQ page here.